Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable... ( Common Genetic Variations Predict P...)

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes

Date:9/22/2008

Common Genetic Variations Predict Patient Response to Novel Beta Blocker

Therapy

TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among heart failure patients with very favorable genotypes, according to results of a large DNA study presented today as a poster at the annual meeting of the Heart Failure Society of America. Researchers found that common genetic variations can predict which heart failure patients will have the greatest therapeutic response to bucindolol.

ARCA biopharma has submitted a New Drug Application (NDA) for bucindolol to the U.S. Food and Drug Administration for the treatment of chronic heart failure.

"The ability to predict patient response to bucindolol makes it easier for physicians to match the right patient to the right medicine, potentially avoiding months of trial-and-error therapy and helping very sick heart failure patients achieve better outcomes sooner," said Christopher O'Connor, M.D., Director of the Heart Center at Duke University Medical Center and presenter of the study. "This data brings us much closer to realizing the benefits of personalized medicine in heart failure."

The prospectively-designed DNA sub-study included more than 1,000 patients enrolled in the Beta-Blocker Evaluation of Survival Trial (BEST), the largest heart failure mortality trial conducted primarily in the United States. Researchers evaluated therapeutic response to bucindolol among patients with genetic variations, or polymorphisms, in two adrenergic receptors that help regulate cardiac function: beta 1 389 Arg/Gly and alpha 2c 322-325 WT/Del. Researchers identified three distinct genotypes that predict the effect of bucindolol: very favorable (47% of BEST patients), favorable (40%) and unfavorable (13%).

In the study, patients with the very favorable genotype
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice

Post Your Comments:

(Date:2/8/2010)... China , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... modernized traditional Chinese medicine ("TCM") based in Chengdu, ... ended December 31, 2009 . , , ... $14.9 Million, Net Income Increased, ... of $0.11 on a diluted basis, ...

(Date:2/8/2010)... Mass. , Feb. 8 ... working with maternal-fetal-medicine doctors by attending the Society ... Center has been working with perinatologists and Ob/Gyn ... Torchilin , CEO of Biocell Center Corporation. "We ... on mothers and families and we are hoping ...

(Date:2/8/2010)... announced today that it has been selected by Invida Group, ... Pacific, to develop and execute its corporate communications and public ... ... (Vocus) February 8, 2010 -- LaVoie Group , a ... been selected by Invida Group , the leading provider ...

(Date:2/5/2010)... passed as fact among historians, journalists and politicians, and ... floor of the U.S. Congress: British forces used chemical ... , But that claim has never been fully squared ... historian at Colgate University. According to Douglas,s research, forthcoming ... Modern History , no such incident ever occurred. ...

[0] Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results [0] Biocell Center Furthers Its Commitment to Maternal-Fetal Medicine [0] Invida Selects LaVoie Group as Public Relations Agency of Record [0] Despite claims, UK did not gas Iraqis in the 1920s, new research finds

... Calif., March 25 WaferGen,Biosystems, Inc. (OTC ... gene expression, genotyping, cell biology and stem ... an exclusive distribution,agreement for the company,s SmartSlide(TM) ... United Kingdom and Labtech France in,France. The ...

... March 25, Galil Medical, a global cryotherapy company,today ... President and,Chief Executive Officer. Galil Medical is a ... treatment of cancerous and,non-cancerous tumours. Mr. Emerson is ... was most recently President and CEO of,American Medical ...

... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider ... Meeting originally scheduled for March 25, 2008 has been,adjourned ... 2008 Annual General Meeting, the required quorum of a,majority ... with,Antigua law, the meeting is adjourned to April 8, ...

Other Biology Technology:WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 2 WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 3 WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 4 WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 5 Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer 2 Sinovac Announces Adjournment of Annual General Meeting 2

WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer Sinovac Announces Adjournment of Annual General Meeting

(Date:2/9/2010)... virus, or VSV, has long been a model system ... RNA viruses, which include viruses that cause influenza, measles ... shown that VSV has the potential to be genetically ... selectivity in killing cancer cells while sparing healthy cells, ... , For such modifications to occur, however, scientists must ...

(Date:2/9/2010)... 9 DigitalPersona, Inc., a ... continues to expand its leadership in fingerprint ... The latest version of the popular ... featuring U.are.U® fingerprint biometrics technology from DigitalPersona, ... National Dealer Conference in Austin, TX. ...

(Date:2/8/2010)... diet may help people avoid the small areas of ... and memory, according to a study released today that ... 62nd Annual Meeting in Toronto April 10 to April ... who ate a Mediterranean-like diet were less likely to ... linked to thinking problems. , The Mediterranean diet ...

Breaking Biology News(10 mins):Researchers reveal 3-D structure of bullet-shaped virus with potential to fight cancer, HIV 2 Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 2 Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 3 Mediterranean diet may lower risk of brain damage that causes thinking problems 2 Practice makes perfect motor memory possible for neuroprosthetic control 13109 1 Practice makes perfect motor memory possible for neuroprosthetic control 13109 2 Practice makes perfect motor memory possible for neuroprosthetic control 13109 3 Laser technology creates new forms of metal and enhances aircraft performance 13107 1 Laser technology creates new forms of metal and enhances aircraft performance 13107 2 NIH funds support UAB joint replacement research 13105 1 NIH funds support UAB joint replacement research 13105 2

[0] Researchers reveal 3-D structure of bullet-shaped virus with potential to fight cancer, HIV [0] Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology [0] Mediterranean diet may lower risk of brain damage that causes thinking problems

... new insights into the mechanisms that underlie long-term memory ... , "The more we know about how long-term ... are maintained in the brain, the more we are going ... Glanzman, UCLA professor of physiological science and neurobiology, whose new ...

... available in German . , , Krakow/Halle. Major ... in fighting pathogen assault. Researchers from the Jagiellonian University ... Research (UFZ) characterized genetic variation and detected more than ... Unlike mammals, not much has been known until now ...

... published this week in Nature, the authors ... for Australian Weather and Climate Research say that ... process in controlling responses of many ecosystems particularly ... , "However, there have been significant discrepancies between real-world ...

Other Biology News:Study of marine snail leads to new insights into long-term memory 2 Study of marine snail leads to new insights into long-term memory 3 Study of marine snail leads to new insights into long-term memory 4 New findings on immune system in amphibians 2 Scientists may have solved an ecological riddle 2

Study of marine snail leads to new insights into long-term memory New findings on immune system in amphibians Scientists may have solved an ecological riddle

... PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 - 2.0 Bleomycin ... 6.0 Loss On Drying: less than or equal to 6.0% ... A 2 : 55 - 70% B 2 : 25 ... or equal to 90% B 4 : less than or ...

... critical performance for all vacuum requirements. A ... performance to suit all applications. The large, ... of proper oil levels at a glance. ... to work with all Thermo Savant SpeedVac ...

6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...

This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....

Biology Products:

Bleomycin sulfate, Unconjugated from USB Corp.VLP285 Oil Vacuum Pump from Thermo Scientific Six Paq, rTth DNA Polymerase, XL and XL Buffer II Pack from Applied Biosystems Spacer for Miniature FRENCH Pressure Cell from Thermo Scientific

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable...( Common Genetic Variations Predict P...)